BTIG initiated coverage of Genmab with a Buy rating and $44 price target. Genmab is a “platform-innovating” biotechnology company with a management team that has generated eight marketed therapeutics to date, the analyst tells investors in a research note. The analyst sees Genmab’s “20 years of relentless platform refinement to be well-positioned to produce the next round of important therapeutics.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Announces Financial Results for the First Half of 2023
- Genmab Updates 2023 Financial Guidance
- Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
- Genmab reports Q2 worldwide net sales of DARZALEX $2.43B
